key: cord-1005193-4jagpw8e authors: Li, Juan; Li, Shuang-Xi; Zhao, Li-Fang; Kong, De-Liang; Guo, Zhi-Yong title: Management recommendations for patients with chronic kidney disease during the novel coronavirus disease 2019 (COVID-19) epidemic date: 2020-05-13 journal: Chronic Dis Transl Med DOI: 10.1016/j.cdtm.2020.05.001 sha: 73bbe26579bb9e599627c6c4f5467fb98e194e08 doc_id: 1005193 cord_uid: 4jagpw8e nan was announced as "severe acute respiratory syndrome coronavirus 2" (SARS-CoV-2) by the International Virus Classification Commission. 4 The WHO declared COVID-19 as a pandemic on March 11, 2020 . The coronavirus family was responsible for two previous pandemic outbreaks of infectious respiratory diseases: severe acute respiratory syndrome (SARS) and middle east respiratory syndrome (MERS). In comparison with SARS and MERS, COVID-19 is more contagious and has a lower fatality rate. 5 The morbidity and fatality of COVID-19 are much higher in members of the senior population who manifest multiple comorbidities. 6 Patients with chronic kidney disease (CKD) usually have several comorbidities, such as hypertension, diabetes, and cardiovascular diseases. CKD is a global public health problem with a total of approximately 850 million patients with CKD worldwide. 7 In China, the incidence of CKD is 10.8 % and estimates indicate that 119.5 million Chinese adults have CKD. 8 Patients with CKD are highly susceptible to COVID-19. In addition, patients on hemodialysis need to visit the dialysis center regularly three times every week. Therefore, the dialysis center becomes a potential vector responsible for spreading this pandemic. In previous epidemics or catastrophic situations, the fatality rate was much higher in patients on dialysis than that in the general population. 5 This review aims to provide management recommendations for patients with CKD during the COVID-19 epidemic period. There is no evidence that COVID-19 infection affects the kidneys in patients with mild-to-moderate illness. However, kidney abnormalities are observed in 20%-63 % of the severe patients who require hospitalization. These are manifested as the presence of protein and red blood cells in the urine; a small proportion had elevated levels of plasma creatinine (19 %) and urea nitrogen (27 %). 9 In a case series of 710 patients with COVID-19, the incidence of proteinuria and hematuria on admission was reported to be 44% and 22%, respectively. 10 suggesting direct tubular injury from the virus. 11 It is difficult to evaluate the precise incidence of AKI in patients with COVID-19. The incidence of AKI in published reports is 2%-5%. However, most of them were from severely ill hospitalized patients. Therefore, the risk in patients with mild illness might be much lower. The incidence of AKI in SARS patients with normal kidney function (without underlying CKD) is reported to be 6.7 %; this was mostly due to ATN and occasional rhabdomyolysis. 12 Moreover, it may even lead to a multiple organ dysfunction syndrome (MODS). The SARS-CoV-2 binds to the angiotensin-converting enzyme 2 (ACE2) and dipeptidyl peptidase (DPP4). These enzymes are highly expressed in the kidneys; they might serve as binding sites for the virus and cause kidney injury. Although the mortality rate is much higher in SARS patients with AKI than those without AKI (92% vs8 %), 12 it remains unknown whether AKI leads to increased mortality in patients with COVID-19. 6, 9 In literature, approximately 15%-30 % of patients with COVID-19 manifest hypertension. 13 Hypertension is assumed to be an independent risk factor for developing COVID-19 and worsening the disease severity. To date, we have no evidence to support the relationship between hypertension and COVID-19. Hypertension increases with age. The COVID-19 disease is more severe and displays worse outcomes in the elderly population. 14,15 After adjustment of age, the association between COVID-19 and hypertension was non-existent. 16 Many coronaviruses, including the SARS-CoV-2, enter the cells by binding to the ACE2 receptor. Therefore, the risk and severity of COVID-19 might vary with the level of ACE2 receptor. 13 The angiotensin-converting enzyme inhibitor (ACEI) and angiotensin receptor blocker (ARB) are widely used as medications in the treatment of hypertension. As the application of ACEI and ARB leads to an increase in the concentration of ACE2, some doctors question its ability to increase the risk and severity of developing COVID-19 as well. 13 Neither clinical data nor basic scientific evidence supports this assumption. Therefore, patients who take ACEI or ARB are not advised to change their therapy. 13 Firstly, SARS-CoV-2 enters the human body through the human ACE2 and human DPP4 (also known as CD26) as the main receptors. 17, 18 ACE2 and DPP4 are highly expressed in the kidney, especially in the renal tubules. If patients with CKD get infected with SARS-CoV-2, their renal tubules are likely to be attacked first. Secondly, patients with CKD are generally the elderly population suffering from multiple comorbidities. They usually have imbalanced ratios of CD4 + /CD8 + T cells and decreased activity of natural killer cells. Moreover, some patients with CKD (for whom glomerular disease is the reason for developing CKD), might need to take glucocorticoids and immunosuppressants. This may further lead to impairment of their immune system and create increased susceptibility to COVID-19. Thirdly, there are several small arteries and capillaries in the kidney that may be damaged by the SARS-CoV-2. Further, the entire volume of blood passes through the kidneys several times a day. Hence, the virus and the inflammatory cytokines in the blood flow can damage the kidneys. Lastly, as a severe subgroup of patients with CKD, dialysis patients constitute a more susceptible population. Dialysis patients are recurrently exposed to a possible contaminated environment because their routine treatment usually requires three dialysis sessions per week. 5 Considering all the above reasons, patients with CKD are more vulnerable to COVID-19 than the general population. The development of COVID-19 may worsen the impaired kidney function and further lead to rapid deterioration of kidney function and even death. 1. Full protection, including waterproof isolation clothing, hair caps, goggles, gloves, and medical masks (surgical mask or the N95 mask) should be undertaken by all the personnel involved in direct patient care. Hand hygiene should be strictly implemented. 4. Unnecessary hospital visits should be avoided because patients with CKD are susceptible to COVID-19 and hospitals are high-risk places with some potentially-infected patients. The maximum possible drugs must be procured in every hospital. The necessary drugs must be procured from a nearby pharmacy during a visit to the community hospital for some routine examination. A face mask must be worn during illness and around people or while visiting a health facility. Attending doctors must be contacted using online consultation tools, such as professional medical websites, e-mail, and social media (Facebook, WeChat, etc). Diet Management: Extra attention should be paid to food safety and food hygiene issues. Food intake should be diversified. The daily meals should include cereals, vegetables and fruits, livestock, poultry, fish, eggs, milk, soybeans, etc. The protein intake should be reasonably guaranteed. The daily protein intake of non-dialyzed CKD patients should preferably range from 0.6-0.8 g/kg/d; a high-quality protein intake comprising fish, shrimp, lean meat, eggs, beans, etc. should account for 60%-70 % of the total food constituents. The intake of salt, potassium, phosphorus, and purines should be strictly limited. Moderate amounts of milk and water should be consumed and carbonated drinks, coffee, and alcohol should be avoided. In summary, severe COVID-19 infection may damage the kidney and cause ATN, leading to proteinuria, hematuria, and elevated serum creatinine. Neither clinical data nor basic scientific evidence supports the idea that ACEI or ARB can increase the risk and severity of developing COVID-19. Therefore, patients who receive ACEI or ARB should not change their therapy unless advised by their physician. Patients with CKD are highly susceptible to COVID-19. Strict comprehensive protocols should be followed to prevent the spread of COVID-19 among patients and healthcare providers. The study was supported by the grants from the National Natural Science Foundation of China (No. 81500583). Clinical features of patients infected with 2019 novel coronavirus in Wuhan Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study COVID-19) Pandemic. Geneva:World Hearth organization Recommendations for the prevention, mitigation and containment of the emerging SARS-CoV-2 (COVID-19) pandemic in haemodialysis centres Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study Chronic Kidney Disease Diagnosis and Management: A Review Prevalence of chronic kidney disease in China: a cross-sectional survey Caution on Kidney Dysfunctions of 2019-nCoV Patients Kidney disease is associated with in-hospital death of patients with COVID-19 Human Kidney is a Target for Novel Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection. MedRxic. 2020 Marth 4 Acute renal impairment in coronavirus-associated severe acute respiratory syndrome Hypertension and COVID-19 Arterial hypertension and risk of death in patients with COVID-19 infection: Systematic review and meta-analysis Hypertension and its severity or mortality in Coronavirus Disease 2019 (COVID-19): a pooled analysis No adequate evidence indicating hypertension as an independent risk factor for COVID-19 severity Single-cell RNA-seq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to 2019-nCoV infection. Front Med The Novel Coronavirus 2019 epidemic and kidneys Epidemic. International Society of Nephrology None.